勝任細胞市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、應用、最終用戶、地區和競爭格局分類，2021-2031年）

全球勝任細胞市場預計將從 2025 年的 21.5 億美元成長到 2031 年的 38.8 億美元，年複合成長率為 10.34%。

這個市場主要由經過物理或化學改造以接受外源遺傳物質的細菌細胞組成，這些細菌細胞是重組蛋白質表現和分子克隆的關鍵工具。該領域的成長主要受生物治療藥物需求不斷成長以及基因工程在工業界和學術界應用日益廣泛所驅動。此外，藥物研發管線中強力的研發舉措也推動了這一成長，這些試劑對於文庫建構和DNA擴增至關重要。根據國際藥品製造商和公司聯合會（IFPMA）的數據，到2024年，全球藥物研發管線將包含超過12,700種處於不同研發階段的藥物。

儘管成長前景強勁，但市場仍面臨維持細胞活性所需的嚴格低溫運輸物流的重大挑戰。勝任細胞對溫度變化極為敏感，在處理和運輸過程中需要持續的超低溫儲存。任何環境條件的波動都可能顯著降低轉換效率，導致實驗失敗，並增加商業和研究實驗室的營運成本。

市場促進因素

全球勝任細胞市場的主要驅動力是生物製藥和重組蛋白生產需求的不斷成長。隨著生物製藥公司將重心從小分子藥物轉向重組疫苗和單株抗體等大分子療法，它們越來越依賴高效的勝任細胞進行蛋白質表現和質體克隆。這些細胞是擴增下游生物製藥生產所需遺傳物質的關鍵組成部分，其應用對藥物研發的成功至關重要。這一成長動能十分明顯，根據美國食品藥物管理局（FDA）統計，2023年有55種新型療法核准，截至2024年1月，已有17種新型生物製品核准。

生命科學研究領域私人和政府投資的不斷增加進一步推動了市場成長。這些投資為先進的工作流程和試劑採購提供了必要的資金。良好的資本環境使商業和學術實驗室能夠確保高品質勝任細胞的穩定供應，這對於縮短計劃週期和最大限度地減少實驗誤差至關重要。例如，根據仲量聯行 (JLL) 2024 年 9 月發布的報告，美國生命科學領域的創業投資在今年上半年成長了 34%，預示著研發領域將迎來新的資金流入。此外，公共政策也支持這一趨勢。 2024 年 10 月，英國政府設立了 5.2 億英鎊的生命科學創新製造基金，旨在加強英國國內關鍵診斷試劑和藥品的生產能力。

市場挑戰

嚴格的低溫運輸物流需求是全球勝任細胞市場擴張的一大障礙。勝任細胞對溫度波動高度敏感，需要超低溫儲存才能維持轉化效率。這種脆弱性使得運輸必須採用液態氮或乾冰等特殊且昂貴的運輸通訊協定。這些複雜的物流要求構成了市場准入和成長的巨大障礙，因為即使運輸過程中溫度出現輕微波動，也可能導致細胞完全喪失活性，迫使研究人員放棄實驗並遭受重大經濟損失。

這些營運風險會直接阻礙市場擴充性，對商業和研究實驗室的預算帶來壓力。處理此類敏感材料的財務風險極高，以至於資源往往從創新和採購轉移到風險管理。產品的價值更凸顯了這種經濟負擔的沉重。 2024 年醫療保健分銷聯盟 (HDA) 的一份報告估計，低溫運輸產品的每日成本是標準非溫控藥品的 22 倍。如此巨大的成本差異凸顯了低溫運輸故障帶來的嚴重財務損失，使得各機構在擴大庫存和限制這些關鍵生物工具的市場進入方面格外謹慎。

市場趨勢

由於治療研究中對精準基因操作的需求日益成長，開發高性能的CRISPR最佳化細胞株係正迅速成為關鍵趨勢。製造商正在開發專門的細菌菌株，以穩定大型重複質體有效載荷並降低重組率，這對於可靠的CRISPR-Cas9加工至關重要。產品開發的這項進展直接加速了基因編輯技術從實驗室發現到臨床應用的轉化。為了支持這項商業性進程，Vertex Pharmaceuticals於2023年12月宣布，美國FDA核准了第一個基於CRISPR的基因編輯療法CASGEVY，這是一個具有里程碑意義的事件，標誌著基因組醫學對先進試劑的依賴性日益增強。

同時，與合成生物學相契合的晶圓代工廠工作流程的快速發展，正推動著向自動化友善、高通量活性細胞形式的轉變。實驗室擴大使用自動化液體處理系統，這些系統需要將包裝好的細胞置於384孔或96孔盤中進行大規模DNA組裝技術，例如Gibson組裝和Golden Gate分析。確保大規模實驗批次轉化效率一致的試劑對於生物學的產業化至關重要。大量的資本投資為這項業務擴張提供了支持。 SynBioBeta預測，到2023年，合成生物學Start-Ups將籌集69億美元的投資資金，用於支持高度依賴這些專業生物工具的自動化基礎設施的發展。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球勝任細胞市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按類型（化學勝任細胞、電勝任細胞）
  • 依應用領域（蛋白質表現、克隆、生物技術、其他應用）
  • 依最終用戶（製藥/生技公司、學術研究機構、受託研究機構(CRO) 等）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美勝任細胞市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章 歐洲勝任細胞市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區勝任細胞市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章 中東和非洲勝任細胞市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲勝任細胞市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球勝任細胞市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Promega Corporation
• Takara Bio Inc.
• New England Biolabs Inc.
• Bio-Rad Laboratories, Inc.
• Transgen Biotech Co., LTD
• Agilent Technologies, Inc.
• Illumina, Inc.
• OriGene Technologies, Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Competent Cells Market is projected to expand from USD 2.15 Billion in 2025 to USD 3.88 Billion by 2031, reflecting a CAGR of 10.34%. This market consists of bacterial cells that have been physically or chemically modified to accept foreign genetic material, acting as essential tools for recombinant protein expression and molecular cloning. The sector's growth is largely driven by rising demand for biologic therapeutics and the broadening application of genetic engineering within both industrial and academic landscapes. Furthermore, strong research initiatives within pharmaceutical pipelines support this expansion, as these reagents are crucial for library generation and DNA amplification. According to the International Federation of Pharmaceutical Manufacturers and Associations, the global pharmaceutical pipeline included over 12,700 medicines across various developmental stages in 2024.

Despite this robust growth outlook, the market encounters significant obstacles regarding the rigorous cold chain logistics needed to preserve cell viability. Because competent cells are extremely susceptible to temperature changes, they require continuous ultra-low temperature storage throughout handling and transport. Any fluctuation in these specific environmental conditions can severely diminish transformation efficiency, resulting in experimental failures and escalating operational expenses for commercial laboratories and research institutions.

Market Driver

A primary catalyst for the Global Competent Cells Market is the escalating demand for the production of biologics and recombinant proteins. As biopharmaceutical organizations transition their focus from small-molecule drugs to large-molecule therapeutics, such as recombinant vaccines and monoclonal antibodies, the dependency on high-efficiency competent cells for protein expression and plasmid cloning has deepened. These cells act as essential components for amplifying the genetic material needed for downstream biologic manufacturing, making their usage integral to the success of drug development efforts. According to the U.S. Food and Drug Administration, this surge in activity is evident, as the agency approved 55 novel therapeutics in 2023, including 17 new biological products as of January 2024.

Market growth is further energized by increasing private and government investments in life science research, which supply the necessary capital for advanced workflows and reagent procurement. Strong funding landscapes enable commercial and academic laboratories to secure reliable supplies of high-quality competent cells, which are vital for accelerating project timelines and minimizing experimental variability. For example, JLL reported in September 2024 that venture capital investment in the U.S. life sciences sector rose by 34% during the first half of the year, indicating a fresh wave of capital for R&D. Furthermore, public initiatives support this trajectory; the UK Government announced a £520 million Life Sciences Innovative Manufacturing Fund in October 2024 to strengthen domestic manufacturing capacities for essential diagnostics and medicines.

Market Challenge

The strict necessities of cold chain logistics pose a major hurdle to the expansion of the Global Competent Cells Market. Because competent cells are highly vulnerable to temperature variations, they must be kept at ultra-low temperatures to maintain their transformation efficiency. This fragility demands specialized, expensive shipping protocols utilizing liquid nitrogen or dry ice. The intricacy of these logistical requirements establishes a formidable barrier to entry and growth, as even slight temperature deviations during transport can lead to total cell viability loss, compelling researchers to abandon experiments and absorb substantial financial setbacks.

These operational hazards directly impede market scalability by pressuring the budgets of commercial laboratories and research institutions. The financial risks involved in handling such sensitive materials are extraordinarily high, often shifting resources from innovation and procurement toward risk management. The magnitude of this economic strain is highlighted by the value of the products; according to the Healthcare Distribution Alliance in 2024, the daily dose of a cold chain product was estimated to cost 22 times more than a standard non-temperature-controlled pharmaceutical. This significant cost gap emphasizes the severe financial liability linked to cold chain failures, prompting organizations to exercise caution in expanding inventory and restricting the broader market accessibility of these critical biological tools.

Market Trends

The creation of competent cell strains optimized for CRISPR is rapidly becoming a significant trend, propelled by the requirement for exact genetic manipulation in therapeutic studies. Manufacturers are developing specialized bacterial strains designed to stabilize large, repetitive plasmid payloads and lower recombination rates, which are crucial for reliable CRISPR-Cas9 processes. This product advancement is directly hastening the transition of gene-editing technologies from laboratory discovery to clinical use. Validating this commercial progress, Vertex Pharmaceuticals reported in December 2023 that the U.S. FDA approved the first CRISPR-based gene-editing therapy, CASGEVY, a historic milestone that highlights the increasing dependence on advanced reagents for genomic medicine.

Simultaneously, the growth of biofoundry workflows aligned with synthetic biology is driving a transition toward automation-compatible, high-throughput competent cell formats. Laboratories are increasingly utilizing automated liquid handling systems to perform large-scale DNA assembly techniques, such as Gibson Assembly and Golden Gate, requiring cells packaged in 384-well or 96-well plate configurations. This industrialization of biology necessitates reagents that guarantee uniform transformation efficiencies across high-volume experimental batches. This operational expansion is backed by significant capital investment; according to SynBioBeta's May 2024 report, synthetic biology startups secured $6.9 billion in investment capital in 2023, funding the growth of automated infrastructure that relies heavily on these specialized biological tools.

Key Market Players

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Promega Corporation
• Takara Bio Inc.
• New England Biolabs Inc.
• Bio-Rad Laboratories, Inc.
• Transgen Biotech Co., LTD
• Agilent Technologies, Inc.
• Illumina, Inc.
• OriGene Technologies, Inc

Report Scope

In this report, the Global Competent Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Competent Cells Market, By Type

• Chemically Competent Cell
• Electrocompetent Cells

Competent Cells Market, By Application

• Protein Expression
• Cloning
• Biotechnology
• Other Applications

Competent Cells Market, By End User

• Pharmaceutical and Biotechnology Companies
• Academic Research Institutes
• Contract Research Organizations (CROs)
• others

Competent Cells Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Competent Cells Market.

Available Customizations:

Global Competent Cells Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Competent Cells Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Chemically Competent Cell, Electrocompetent Cells)
  • 5.2.2. By Application (Protein Expression, Cloning, Biotechnology, Other Applications)
  • 5.2.3. By End User (Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations (CROs), others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Competent Cells Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Competent Cells Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Competent Cells Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Competent Cells Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Competent Cells Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Competent Cells Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Competent Cells Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Competent Cells Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Competent Cells Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Competent Cells Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Competent Cells Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Competent Cells Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Competent Cells Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Competent Cells Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Competent Cells Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Competent Cells Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Competent Cells Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Competent Cells Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Competent Cells Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Competent Cells Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Competent Cells Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Competent Cells Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Competent Cells Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Competent Cells Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Competent Cells Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck KGaA
• 15.3. Promega Corporation
• 15.4. Takara Bio Inc.
• 15.5. New England Biolabs Inc.
• 15.6. Bio-Rad Laboratories, Inc.
• 15.7. Transgen Biotech Co., LTD
• 15.8. Agilent Technologies, Inc.
• 15.9. Illumina, Inc.
• 15.10. OriGene Technologies, Inc

16. Strategic Recommendations

17. About Us & Disclaimer